Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab plus chlorambucil in untreated CLL
NCT01868893Phase 2Completed
- Sponsor
- Genentech
- Start
- Aug 2013
- Primary completion
- Jan 2014
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of obinutuzumab in chronic lymphocytic leukemia (CLL), sponsored by Genentech. Started Aug 2013; status: completed.
02
Drugs
obinutuzumab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT01868893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01868893.